Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 14/20 | 0.81 |
| ▸ | PPARG | P37231 | 7/20 | 0.81 |
| ▸ | PPARA | Q07869 | 6/20 | 0.69 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.55 |
| ▸ | VDR | P11473 | 9/20 | 0.53 |
| ▸ | ESR1 | P03372 | 3/20 | 0.53 |
| ▸ | THRA | P10827 | 3/20 | 0.53 |
| ▸ | THRB | P10828 | 3/20 | 0.53 |
| ▸ | RXRA | P19793 | 3/20 | 0.53 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.53 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6236889 | 0.89 | PPARD (1.00) | PPARDPPARGPPARAPTPN1VDR | |
| SCHEMBL6239392 | 0.87 | PPARD (0.68) | PPARDPPARGPPARAPTPN1VDR | |
| SCHEMBL6237599 | 0.87 | PPARD (0.82) | PPARDPPARGPPARAPTPN1VDR | |
| SCHEMBL5515757 | 0.86 | PPARD (0.66) | PPARDPPARGPPARAVDRESR1 | |
| SCHEMBL6261549 | 0.84 | PPARD (0.69) | PPARDPPARGPPARAPTPN1VDR | |
| Acrylic Acid SCHEMBL6260476 | 0.84 | PPARD (0.89) | PPARDPPARGPPARAPTPN1VDR | |
| SCHEMBL6240464 | 0.83 | PPARD (0.65) | PPARDPPARGPPARAVDRESR1 | |
| SCHEMBL6236852 | 0.82 | PPARD (1.00) | PPARDPPARGPPARAPTPN1VDR | |
| SCHEMBL6261545 | 0.81 | PPARD (0.82) | PPARDPPARGPPARAPTPN1VDR | |
| SCHEMBL6261551 | 0.81 | PPARD (0.82) | PPARDPPARGPPARAPTPN1VDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189895-B8 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2005-11-09 | — | — | EP | disclosed |
| EP-1189895-B1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2005-06-08 | — | — | EP | disclosed |
| US-6723740-B2 | ADMINISTERING THERAPEUTIC AMOUNT OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA AGONIST TO LOWER TRIGLYCERIDES | SMITHKLINE BEECHAM CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-6710063-B1 | Activators of PPAR delta | SMITHKLINE BEECHAM CORPORATION | 2004-03-23 | — | — | US | disclosed |
| US-20030203947-A1 | Administration of a therapeutic amount of a 1,3-thiazole-5-yl methylsulfanyl or 1,3-oxazole-5-yl methylsulfanyl derivative to a patient for lowering triglycerides | CHAO ESTHER YU-HSUAN (US) | 2003-10-30 | — | — | US | disclosed |
| EP-1189895-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXO GROUP LIMITED (GB) | 2002-03-27 | — | — | EP | disclosed |
| WO-2001000603-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXO GROUP LIMITED (GB) | 2001-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030203947-A1 | Administration of a therapeutic amount of a 1,3-thiazole-5-yl methylsulfanyl or 1,3-oxazole-5-yl methylsulfanyl derivative to a patient for lowering triglycerides | PPARA, PPARD, PPARG | PPARD 2/4885PPARG 3/4885PPARA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.